Table 3.

Recurrences and disease-free survival in 181 node-negative breast cancer patients after different adjuvant systemic therapies or no therapy

Subgroup		n	Recurrence (n [%])	DFS (P)
Chemotherapy (n = 61)
c-myc	Amplified	19	3 (15.8)	0.1748
	Nonamplified	42	2 (4.8)
HER-2/neu	Amplified	26	1 (3.8)	0.2552
	Nonamplified	35	4 (11.4)
Endocrine therapy (n= 99)
c-myc	Amplified	15	1 (6.7)	0.3325
	Nonamplified	84	2 (2.4)
HER-2/neu	Amplified	22	1 (4.5)	0.6641
	Nonamplified	77	2 (2.6)
No therapy (n = 21)
c-myc	Amplified	5	1 (20.0)	0.0209*
	Nonamplified	16	0 (0)
HER-2/neu	Amplified	7	0 (0)	0.4969
	Nonamplified	14	1 (7.1)

*P < 0.05 (log-rank test). DFS, disease-free survival.